1 / 51

Hodgkin Lymphoma Board Review

Hodgkin Lymphoma Board Review . Brad Kahl, MD 11/18/03. Hodgkin Lymphoma. Epidemiology Biology Classification Approach to the Patient. Hodgkin Lymphoma. Epidemiology 14% of malignant lymphomas 0.5% of all malignancies approximately 8000 new cases/yr in US approximately 1500 deaths/yr

malcolm
Télécharger la présentation

Hodgkin Lymphoma Board Review

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hodgkin Lymphoma Board Review Brad Kahl, MD 11/18/03

  2. Hodgkin Lymphoma • Epidemiology • Biology • Classification • Approach to the Patient

  3. Hodgkin Lymphoma • Epidemiology • 14% of malignant lymphomas • 0.5% of all malignancies • approximately 8000 new cases/yr in US • approximately 1500 deaths/yr • over past 30 years • age adjusted incidence rates declined appreciably • mortality rates declined substantially

  4. Trends in Cancer Mortality Rates, Men, 1973-1996

  5. Trends in Cancer Mortality Rates, Women, 1973-1996

  6. Hodgkin Lymphoma • Epidemiology • men > women • whites > blacks > Asians • no clear risk factors, several implicated • woodworking, farming • familial risk • Concordance for HD in twins • 10/179 in monozygotic vs 0/187 in dizygotic twins (Mack et al, NEJM 1995)

  7. Hodgkin Lymphoma • Risk Factors con’t • HIV • increases risk for HD 8 fold • HD not an AIDS defining illness • NHL 113x • KS 310x • Unclear why risk for NHL so much greater in HIV patients compared to HD

  8. Hodgkin Lymphoma • Epstein Barr Virus • EBV DNA found in 50% RS cells • pathogen or passenger • Increased risk for HD after infectious mono (Hjalgrim et al, NEJM 2003) • Absolute risk 1/1000 • Median incubation time from mono to EBV+ HD 4.1 years • No increased risk for EBV- HD after mono

  9. Reed-Sternberg Cell

  10. Hodgkin Biology • Hodgkin’s Disease • Reed-Sternberg cell is the malignant cell • 1% of cells in a biopsy specimen • potent cytokine producing cell (at least 12 cytokines) • cytokines appear to drive the disease process • remainder of cells are background inflammatory cells • lymphocytes, plasma cells, macrophages, eosinophils • RS cell as the malignant cell • origin only worked out within the past 5 years

  11. Hodgkin Biology • RS is a “crippled” germinal center B cell • does not have normal B cell surface antigens • micromanipulation of single RS followed by PCR demonstrates clonally rearranged, but non functional immunoglobulin genes • somatic mutations result in stop codon (no sIg) • no apoptotic death malignant transformation • unclear how this occurs; ? EBV • unclear how cells end up with RS phenotype

  12. Hodgkin Lymphoma Classification • “Classic” Hodgkin’s Disease • nodular sclerosis • mixed cellularity • lymphocyte depleted (very rare) • classical lymphocyte rich • HRS cells CD30 and CD15 positive • nodular lymphocyte predominant • HRS cells (L&H cells) have B cell markers • CD 20 and surface Immunoglobulin

  13. NLP Hodgkin Lymphoma • differs from classical HD clinically and histopathlogically • preference for peripheral nodal sites • early stage distribution • late median time to recurrence • late recurrences common • low mortality from HD • L&H cells • express CD 20 (B cell marker) • express surface Ig

  14. Nodular Lymphocyte Predominant Hodgkin Lymphoma

  15. Nodular Lymphocyte Predominant Hodgkin Lymphoma

  16. Nodular Lymphocyte Predominant Hodgkin Lymphoma

  17. Nodular Lymphocyte Predominant Hodgkin Lymphoma • Management • No consensus • often treated like classical hodgkins • My view is “do not overtreat” as cure is unlikely and as many deaths from second malignancies as from LPHD (possible related to HD therapy) • I believe watch and wait is reasonable • Often can do IFRT to problem areas as they appear • Rituximab effective in relapse with ORR 85-100%.

  18. Classic Hodgkin Lymphoma

  19. Nodular Sclerosing Hodgkin Lymphoma

  20. Mixed Cellularity Hodgkin Lymphoma

  21. Nodular Lymphocyte Rich Classical Hodgkin Lymphoma

  22. Lymphocyte Depleted Hodgkin Lymphoma

  23. Hodgkin Lymphoma: approach to patient • staging evaluation • H & P • CBC, diff, plts • ESR, LDH, albumin, LFT’s, Cr • CT scans chest/abd/pelvis, CXR • bone marrow evaluation (for stage IIB and higher) • PET scan may be helpful • PFTs, LVEF when clinically indicated • Fertility counseling • **lymphangiogram or laparotomy**

  24. Modified Ann Arbor Staging Stage I Involvement of a single lymph node region Stage II Involvement of  2 lymph node regions on the same side of the diaphragm Stage III Involvement of lymph node regions on both sides of the diaphragm Stage IV Multifocal involvement of  1 extralymphatic sites ± associated lymph nodes or isolated extralymphatic organ involvement with distant nodal involvement Cancer. 1982;49:2112.

  25. Ann Arbor Staging System for Hodgkin's Disease and Non-Hodgkin's Lymphoma Stage I Stage II Stage III Stage IV Reprinted with permission. Adapted from Skarin. Dana-Farber Cancer Institute Atlas of Diagnostic Oncology. 1991.

  26. Modified Ann Arbor Staging • “E” designation for extranodal disease • B symptoms • recurrent drenching night sweats during previous month • unexplained, persistent, or recurrent fever with temps above 38 C during the previous month • unexplained weight loss of more than 10% of the body weight during the previous 6 months • Criteria for bulk • 10 cm nodal mass • mediastinal mass > 1/3 thorax diameter

  27. Hodgkin Lymphoma: Prognostic Factors • Adverse prognostic features for stage I & II (EORTC data) • more than 3 nodal sites • bulky adenopathy • ESR > 50 • B symptoms • invasion into critical organs • male • age > 40 • MC or LD subtype • should probably not receive XRT alone if any of the above present (excessive relapse rate)

  28. Hodgkin Lymphoma: Prognostic Factors • Independent adverse prognostic factors • advanced stage (III-IV) • male sex • age > 45 • albumin < 4 gm/dl • HgB < 10.5 mg/dl • stage IV disease • WBC count > 15,000/mm3 • lymphocyte count < 600/mm3 (Hasenclever et al, NEJM 339,1506-1514;1998)

  29. Hodgkin Lymphoma: Prognostic Factors

  30. Hodgkin Lymphoma: Biologic Prognostic Factors • Favorable • EBV in tumor cells • Unfavorable • Tissue eosinophila (NSHD) • Lymphocyte depletion (NSHD) • RS atypia (NSHD) • Bcl-2 overexpression • P53 • High proliferative rate

  31. Hodgkin Lymphoma • Treatment • approach depends upon stage, prognostic factors, and co-morbidities • Stage I-II • consider XRT, chemotherapy, or combined therapy • Bulky stage I-II • combined modality therapy, usually 6 cycles of chemotherapy • Stage III-IV • ABVD x 6-8 cycles gold standard

  32. Hodgkin Lymphoma • Results of Treatment stage5 year overall survival • I 90% • II 90% • III 80% • IV 65%

  33. Hodgkin Lymphoma: Treatment of limited stage disease • Current general consensus is to administer CMT • ABVD x 4 (consider 6 cycles for bulk) • Followed by IFRT • Definite trend towards limiting the radiation field and possibly lowering the radiation dose due to concern over late effects • Data from 2 large trials • #1: Institute Nazionale Tumori • Enrolled patients with stage I, IIA, IIA bulky, and IIEA • Data presented at 2001 ASH meeting

  34. Hodgkin Lymphoma: Treatment of limited stage disease

  35. Hodgkin Lymphoma: Treatment of limited stage disease

  36. Hodgkin Lymphoma: Treatment of limited stage disease • Study #2: Engart et al, JCO Oct 2003. • Included patients with limited stage HD and at least one risk factor • Bulky mediastinal disease • Extranodal disease • Massive splenic disease • ESR > 50 and no B symptoms • ESR > 30 and B symptoms • More that 2 lymph node regions

  37. Hodgkin Lymphoma: Treatment of limited stage disease

  38. Hodgkin Lymphoma: Treatment of limited stage disease

  39. Hodgkin Lymphoma: Treatment of limited stage disease • More acute toxicities in EFRT • Late toxicities (second CA, cardiac, pulmonary) not statistically different • Trend worse in EFRT arm • Longer follow up will needed • Conclusion from trials 1 and 2 • 4 cycles of chemotherapy plus IFRT equally effective to treatment plans including larger radiation fields

  40. Hodgkin Lymphoma • Excess death rate (relative)* (SEER data) • 2 years: 5.6% • 5 years: 8.8% • 10 years: 14.3% • 15 years: 19.4% • 20 years: 23.9% *compared to age and sex matched control (deaths other than from Hodgkins)

  41. Hodgkin Lymphoma: Late Complications • Radiotherapy appears to confer the most late risk • Actuarial rate of second CA 1%/year with no plateau • In one study the 25 year cumulative risk of breast CA was 16.3% • Current major focus of current clinical trials to to maintain high cure rate while minimizing late complication • shorter courses of chemotherapy with lower radiation doses in smaller fields • elimination of radiotherapy (some argue for this already)

  42. Hodgkin Lymphoma • Current EORTC trial for stage I-II patients • EBVP x 6 + 36 Gy IF • EBVP x 6 + 20 Gy IF • EBVP x 6 (arm closed do to excessive relapse) • Current GHSG trial for stage I-II patients • ABVD x 4 + 30 Gy IF • ABVD x 4 + 20 GY IF • ABVD x 2 + 30 Gy IF • ABVD x 2 + 20 GY IF

  43. Hodgkin Lymphoma: Late Complications • Other Late Complications • depends upon treatment modality utilized • XRT vs. MOPP vs. ABVD vs. CMT • issues depends upon the age of patient • relative risks higher in younger patients • absolute risks higher in older patients • Risks of leukemia and infertility appear substantially lower using ABVD rather than MOPP • Infertility 20% vs. 50-70% • Pulmonary-Bleomycin, Cardiac-adriamycin

  44. Hodgkin Lymphoma: Advanced Disease • More straightforward right now • ABVD is standard • Treat until CR + 2 cycles up to maximum of 8 • No role for routine XRT after chemo • (Aleman et al, NEJM June 2003) • Common practice is to administer consolidative XRT to bulky mediastinal disease after chemo • Stanford V, BEACOPP being compared to ABVD in prospective clinical trials currently

  45. Hodgkin Lymphoma: Stem Cell Transplant • Reserved for patients who relapse after chemotherapy (autologous) • Superior to additional conventional chemotherapy in RCT • (Schmitz et al, Lancet 2002) • Upfront transplant for poor prognosis disease does not appear superior (2 trials) • Beneficial for the small group of patients with primary refractory HD

  46. Hodgkin Lymphoma: Stem Cell Transplant

  47. Lymphoma and Pregnancy • 4th most common malignancy among pregnant females (breast > cervical > ovarian) • no good evidence that pregnancy has a prognostic influence on the lymphoma (except Burkitts) • Staging Issues • CT scans and radioisotope scans contraindicated • rely on PE, labs, CXR, US, MRI, and marrow

  48. Lymphoma and Pregnancy • Therapy during pregnancy • choices will vary on case by case basis • type of lymphoma, gestational age, personal beliefs • therapeutic abortion vs watchful waiting vs limited XRT vs chemotherapy • Indolent NHL (rare) and some Hodgkins • will be able to defer therapy until after delivery

  49. Lymphoma and Pregnancy • Aggressive NHL and Hodgkins requiring therapy • 2nd and 3rd trimester • data suggests can give combination chemotherapy with minimal risk to fetus (CHOP or ABVD) • need to plan delivery to avoid neutropenia and thrombocytopenia • 1st trimester (most difficult situation) • consider therapeutic abortion • risk of fetal malformation with combination chemo approximately 20%

More Related